CombiMatrix, a CLIA-certified laboratory, is bringing microarray analysis to the underserved problem of recurrent pregnancy loss as well as to prenatal testing. CombiMatrix performs microarray assays ...

An international consortium of genetics experts has issued a consensus statement recommending chromosomal microarray as the new standard practice for genetic evaluation of children with unexplained ...

(HealthDay News) – Microarray analysis can be a useful addition to karyotyping in prenatal testing and appears to be helpful in the investigation of stillbirth, according to two studies published in ...

Midway through her pregnancy four years ago, Denise Bratina got some scary news. Doctors told Bratina, then 37, that amniocentesis results showed that her unborn child was missing a small segment of ...

This initiative supports Astra Biotech’s aim of facilitating early diagnosis of individuals’ risk factors through innovative assays. In this way long-term effects of a disease can be minimised and ...

A large study from Children's Hospital Boston and the Boston-based Autism Consortium finds that a genetic test that samples the entire genome, known as chromosomal microarray analysis, has about three ...

Purpose: Chromosomal microarray (CMA) testing provides the highest diagnostic yield for clinical testing of patients with developmental delay (DD), intellectual disability (ID), multiple congenital ...

New York, NY—A large, multi-center clinical trial led by researchers from Columbia University Medical Center (CUMC) shows that a new genetic test resulted in significantly more clinically relevant ...

A new test may be better at detecting potentially harmful genetic changes in children before they are born than current methods, researchers say. The test, called a chromosomal microarray, detected ...

CombiMatrix, a molecular diagnostics company performing DNA-based testing services for cancer and developmental disorders, today announced that it has entered into a strategic partnership with the ...

The Netherlands Cancer Institute in Amsterdam is to become the first institution in the world to use microarray techniques for the routine prognostic screening of cancer patients. Aiming for a June ...

PathogenDx has announced the release of the first quantitative microarray-based test for cannabis, PDx-Quant™, which can determine whether or not a sample exceeds a state or a federal regulatory ...